Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) insider Edmund Dunn sold 25,164 shares of Monte Rosa Therapeutics stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $18.10, for a total value of $455,468.40. Following the completion of the sale, the insider owned 22,693 shares in the company, valued at approximately $410,743.30. The trade was a 52.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Edmund Dunn also recently made the following trade(s):
- On Monday, March 2nd, Edmund Dunn sold 536 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $17.50, for a total value of $9,380.00.
Monte Rosa Therapeutics Price Performance
NASDAQ GLUE opened at $18.50 on Tuesday. The stock's 50 day simple moving average is $19.92 and its 200-day simple moving average is $13.78. The company has a market cap of $1.20 billion, a PE ratio of 57.81 and a beta of 1.63. Monte Rosa Therapeutics, Inc. has a 1-year low of $3.50 and a 1-year high of $25.77.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the stock. Wedbush reaffirmed an "outperform" rating and set a $37.00 target price on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Piper Sandler reaffirmed an "overweight" rating and set a $37.00 price objective (up from $27.50) on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 14th. Weiss Ratings reiterated a "sell (d)" rating on shares of Monte Rosa Therapeutics in a report on Monday, December 29th. TD Cowen restated a "buy" rating on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Finally, Jefferies Financial Group restated a "buy" rating and issued a $31.00 price target on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $31.33.
Get Our Latest Stock Analysis on Monte Rosa Therapeutics
Institutional Investors Weigh In On Monte Rosa Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in GLUE. GAMMA Investing LLC purchased a new stake in Monte Rosa Therapeutics in the fourth quarter valued at $30,000. Russell Investments Group Ltd. acquired a new stake in shares of Monte Rosa Therapeutics during the 3rd quarter worth about $32,000. Brighton Jones LLC purchased a new stake in Monte Rosa Therapeutics in the 2nd quarter valued at about $48,000. Lazard Asset Management LLC lifted its position in Monte Rosa Therapeutics by 42.9% in the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company's stock valued at $48,000 after buying an additional 3,262 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in Monte Rosa Therapeutics by 16.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company's stock valued at $49,000 after buying an additional 451 shares during the last quarter. Institutional investors and hedge funds own 79.96% of the company's stock.
Monte Rosa Therapeutics Company Profile
(
Get Free Report)
Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.
The company's main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
